세계의 진행성 재발성 난소암 시장 보고서(2025년)

Advanced Recurrent Ovarian Cancer Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

진행성 재발성 난소암 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 주요 동향에는 조기 발견을 위한 인공지능의 사용, 액체 생검 기술의 개발, 바이오마커 기반 치료법의 통합, 유전자 편집 기술의 발전, 정밀 의학의 채택 증가 등이 있습니다.

맞춤형 의료의 중시의 고조는 진행성 재발성 난소암 시장의 성장을 가속할 것으로 예측됩니다. 우리가 결정할 수 있는 것이 배경에 있습니다. 진행성 재발성 난소암은 각 환자의 특정 유전자 돌연변이와 종양의 분자적 특성을 다루는 맞춤형 치료 접근법의 필요성을 강조함으로써 개별화됩니다. 의료의 발전에 공헌하여 치료 성적을 향상시키고 재발률을 저하시킵니다. 예를 들어, 2024년 2월 개인 맞춤형 의약품 도입을 지지하는 미국 단체인 Personalized Medicine Coalition은 미국 식품의약국이 희귀질환 환자를 위한 16개의 새로운 개인 맞춤형 치료제를 승인했으며, 이는 2022년의 6개에서 증가한 수치라고 보고했습니다.

진행성 재발성 난소암 시장의 주요 기업은 치료 정밀도의 향상, 암세포에의 약물 전달의 개선, 오프 타겟 효과의 저감, 종래의 치료법에 대한 내성에의 대응 등을 목적으로, 항체 약물 복합체와 같은 혁신적 치료의 개발을 우선하고 있습니다. 암세포에 특이적인 단클론 항체와 세포독성 약제를 조합한 표적암 치료의 한 형태이며, 종양세포에의 정확한 약물 전달을 확보함과 동시에 건강한 조직에 대한 해를 최소화합니다. 예를 들어, 2024년 1월, 중국 기반 바이오 제약 회사인 RemeGen Co.는 독자적으로 개발한 메소텔린(MSLN) 표적 항체-약물 접합체인 RC88이 백금 내성 재발성 상피성 난소암, 난관암, 원발성 복막암 치료제로 FDA 신속 심사 지정을 받았다고 발표했습니다. 강력한 미세소관 억제제인 모노메틸아우리스타틴 E(MMAE)를 통합한 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 진행성 재발성 난소암 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 진행성 재발성 난소암 시장 : 성장률 분석
• 세계의 진행성 재발성 난소암 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 진행성 재발성 난소암 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 진행성 재발성 난소암 전체 시장(TAM)

제6장 시장 세분화

• 세계의 진행성 재발성 난소암 시장 : 질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 상피성 난소암
• 비상피성 난소암
• 세계의 진행성 재발성 난소암 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 표적 치료
• 화학 치료
• 수술
• 방사선
• 생물학적 치료
• 세계의 진행성 재발성 난소암 시장 : 환자 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 중년(40-59세)
• 소아
• 시니어(60세 이상)
• 청년(18-39세)
• 세계의 진행성 재발성 난소암 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 약국
• 세계의 진행성 재발성 난소암 시장 : 상피성 난소암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 장액성 암종
• 자궁내막암
• 투명 세포 암종
• 점액성 암종
• 세계의 진행성 재발성 난소암 시장 : 비상피성 난소암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 생식세포 종양
• 성선-기질 종양
• 전이성 종양

제7장 지역별/국가별 분석

• 세계의 진행성 재발성 난소암 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 진행성 재발성 난소암 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 진행성 재발성 난소암 시장 : 경쟁 구도
• 진행성 재발성 난소암 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Roche Holding AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Bristol Myers Squibb Company
• AstraZeneca plc
• Novartis International AG
• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Genentech Inc.
• Exelixis Inc.
• Mirati Therapeutics Inc.
• Kite Pharma Inc.
• ImmunoGen Inc.
• Clovis Oncology Inc.
• Debiopharm International SA
• Celsion Corporation

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 진행성 재발성 난소암 시장(2029년) : 새로운 기회를 제공하는 국가
• 진행성 재발성 난소암 시장(2029년) : 새로운 기회를 제공하는 부문
• 진행성 재발성 난소암 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Advanced recurrent ovarian cancer is a form of ovarian cancer that has returned after initial treatment and has progressed beyond the ovaries. This condition is typically classified as stage III or IV, where the cancer may spread to nearby organs in the pelvis or abdomen and potentially metastasize to distant sites, such as the lungs.

The primary types of advanced recurrent ovarian cancer include epithelial ovarian cancer and non-epithelial ovarian cancer. Epithelial ovarian cancer originates in the epithelial cells lining the ovaries, which are responsible for producing eggs and hormones. Treatment options include targeted therapy, chemotherapy, surgery, radiation, and biological therapy. Patients fall into different age groups, including pediatric, young adults (18-39), middle-aged (40-59), and seniors (60+). These treatments are administered in various healthcare settings, such as hospitals, clinics, and pharmacies.

The advanced recurrent ovarian cancer market research report is one of a series of new reports from The Business Research Company that provides advanced recurrent ovarian cancer market statistics, including advanced recurrent ovarian cancer industry global market size, regional shares, competitors with an advanced recurrent ovarian cancer market share, detailed advanced recurrent ovarian cancer market segments, market trends and opportunities, and any further data you may need to thrive in the advanced recurrent ovarian cancer industry. This advanced recurrent ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The advanced recurrent ovarian cancer market size has grown strongly in recent years. It will grow from $2.50 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period was driven by the increasing prevalence of ovarian cancer, limited treatment options for advanced stages, rising awareness of ovarian cancer symptoms, growing healthcare spending, and advancements in chemotherapy regimens.

The advanced recurrent ovarian cancer market size is expected to see strong growth in the next few years. It will grow to $3.75 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The projected growth during the forecast period is driven by an increasing focus on personalized medicine, the expansion of targeted therapies and immunotherapies, rising investment in cancer research, improved healthcare access in emerging markets, and an aging population. Key trends include the use of artificial intelligence for early detection, the development of liquid biopsy technologies, the integration of biomarker-driven therapies, advancements in gene editing technologies, and the growing adoption of precision medicine.

The increasing emphasis on personalized medicine is expected to drive the growth of the advanced recurrent ovarian cancer market. Personalized medicine involves tailoring medical treatment to an individual's genetic profile, lifestyle, and specific health conditions to provide the most effective and targeted therapy. The rise of personalized medicine is fueled by advancements in genomics, biotechnology, and data analytics, allowing for more precise identification of genetic variations and disease biomarkers. Advanced recurrent ovarian cancer contributes to the development of personalized medicine by emphasizing the need for customized treatment approaches that address specific genetic mutations and molecular characteristics of each patient's tumor, thereby improving therapeutic outcomes and reducing recurrence rates. For example, in February 2024, the Personalized Medicine Coalition, a US-based organization advocating for personalized medicine adoption, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. As a result, the growing focus on personalized medicine is fueling the expansion of the advanced recurrent ovarian cancer market.

Leading companies in the advanced recurrent ovarian cancer market are prioritizing the development of innovative treatments, such as antibody-drug conjugates, to enhance treatment precision, improve drug delivery to cancer cells, reduce off-target effects, and address resistance to traditional therapies. Antibody-drug conjugates (ADCs) are a form of targeted cancer therapy that combines a monoclonal antibody specific to cancer cells with a cytotoxic drug, ensuring precise drug delivery to tumor cells while minimizing harm to healthy tissues. For instance, in January 2024, RemeGen Co. Ltd., a China-based biopharmaceutical company, announced that its independently developed RC88, a mesothelin (MSLN)-targeting antibody-drug conjugate, received FDA Fast Track Designation for treating platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancers. This product integrates a recombinant humanized anti-MSLN monoclonal antibody with monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The ADC technology facilitates the precise delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing systemic toxicity. RemeGen utilizes a proprietary bridging technology to optimize the connection between antibodies and drugs.

In February 2024, AbbVie Inc., a US-based pharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. This acquisition aims to strengthen AbbVie's oncology portfolio by incorporating ImmunoGen's expertise in antibody-drug conjugates (ADCs) and its promising treatments for advanced cancers, including ovarian cancer. ImmunoGen Inc. is a US-based company specializing in the development of ADC therapies for cancer treatment.

Major players in the advanced recurrent ovarian cancer market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, GSK plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Exelixis Inc., Mirati Therapeutics Inc., Kite Pharma Inc., ImmunoGen Inc., Clovis Oncology Inc., Debiopharm International SA, Celsion Corporation.

North America was the largest region in the advanced recurrent ovarian cancer market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in advanced recurrent ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced recurrent ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The advanced recurrent ovarian cancer market includes revenues earned by entities by providing services such as diagnostic services, treatment services, and supportive care services, and related products such as pharmaceutical drugs, diagnostic products, medical devices, and supportive care products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Advanced Recurrent Ovarian Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on advanced recurrent ovarian cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for advanced recurrent ovarian cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The advanced recurrent ovarian cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer
• 2) By Treatment Type: Targeted Therapy, Chemo Therapy, Surgery, Radiation, Biological Therapy
• 3) By Patient Age Group: Middle Aged (40-59), Pediatric, Senior (60+), Young Adult (18-39)
• 4) By End User: Hospitals, Clinics, Pharmacies
• Subsegments:
• 1) By Epithelial Ovarian Cancer: Serous Carcinoma; Endometrioid Carcinoma; Clear Cell Carcinoma; Mucinous Carcinoma
• 2) By Non-Epithelial Ovarian Cancer: Germ Cell Tumors; Sex Cord-Stromal Tumors; Metastatic Tumors
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Advanced Recurrent Ovarian Cancer Market Characteristics

3. Advanced Recurrent Ovarian Cancer Market Trends And Strategies

4. Advanced Recurrent Ovarian Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Advanced Recurrent Ovarian Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Advanced Recurrent Ovarian Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Advanced Recurrent Ovarian Cancer Market Growth Rate Analysis
• 5.4. Global Advanced Recurrent Ovarian Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Advanced Recurrent Ovarian Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Advanced Recurrent Ovarian Cancer Total Addressable Market (TAM)

6. Advanced Recurrent Ovarian Cancer Market Segmentation

• 6.1. Global Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithelial Ovarian Cancer
• Non-Epithelial Ovarian Cancer
• 6.2. Global Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Chemo Therapy
• Surgery
• Radiation
• Biological Therapy
• 6.3. Global Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Middle Aged (40-59)
• Pediatric
• Senior (60+)
• Young Adult (18-39)
• 6.4. Global Advanced Recurrent Ovarian Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Pharmacies
• 6.5. Global Advanced Recurrent Ovarian Cancer Market, Sub-Segmentation Of Epithelial Ovarian Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serous Carcinoma
• Endometrioid Carcinoma
• Clear Cell Carcinoma
• Mucinous Carcinoma
• 6.6. Global Advanced Recurrent Ovarian Cancer Market, Sub-Segmentation Of Non-Epithelial Ovarian Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Germ Cell Tumors
• Sex Cord-Stromal Tumors
• Metastatic Tumors

7. Advanced Recurrent Ovarian Cancer Market Regional And Country Analysis

• 7.1. Global Advanced Recurrent Ovarian Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Advanced Recurrent Ovarian Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Advanced Recurrent Ovarian Cancer Market

• 8.1. Asia-Pacific Advanced Recurrent Ovarian Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Advanced Recurrent Ovarian Cancer Market

• 9.1. China Advanced Recurrent Ovarian Cancer Market Overview
• 9.2. China Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Advanced Recurrent Ovarian Cancer Market

• 10.1. India Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Advanced Recurrent Ovarian Cancer Market

• 11.1. Japan Advanced Recurrent Ovarian Cancer Market Overview
• 11.2. Japan Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Advanced Recurrent Ovarian Cancer Market

• 12.1. Australia Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Advanced Recurrent Ovarian Cancer Market

• 13.1. Indonesia Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Advanced Recurrent Ovarian Cancer Market

• 14.1. South Korea Advanced Recurrent Ovarian Cancer Market Overview
• 14.2. South Korea Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Advanced Recurrent Ovarian Cancer Market

• 15.1. Western Europe Advanced Recurrent Ovarian Cancer Market Overview
• 15.2. Western Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Advanced Recurrent Ovarian Cancer Market

• 16.1. UK Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Advanced Recurrent Ovarian Cancer Market

• 17.1. Germany Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Advanced Recurrent Ovarian Cancer Market

• 18.1. France Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Advanced Recurrent Ovarian Cancer Market

• 19.1. Italy Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Advanced Recurrent Ovarian Cancer Market

• 20.1. Spain Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Advanced Recurrent Ovarian Cancer Market

• 21.1. Eastern Europe Advanced Recurrent Ovarian Cancer Market Overview
• 21.2. Eastern Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Advanced Recurrent Ovarian Cancer Market

• 22.1. Russia Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Advanced Recurrent Ovarian Cancer Market

• 23.1. North America Advanced Recurrent Ovarian Cancer Market Overview
• 23.2. North America Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Advanced Recurrent Ovarian Cancer Market

• 24.1. USA Advanced Recurrent Ovarian Cancer Market Overview
• 24.2. USA Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Advanced Recurrent Ovarian Cancer Market

• 25.1. Canada Advanced Recurrent Ovarian Cancer Market Overview
• 25.2. Canada Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Advanced Recurrent Ovarian Cancer Market

• 26.1. South America Advanced Recurrent Ovarian Cancer Market Overview
• 26.2. South America Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Advanced Recurrent Ovarian Cancer Market

• 27.1. Brazil Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Advanced Recurrent Ovarian Cancer Market

• 28.1. Middle East Advanced Recurrent Ovarian Cancer Market Overview
• 28.2. Middle East Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Advanced Recurrent Ovarian Cancer Market

• 29.1. Africa Advanced Recurrent Ovarian Cancer Market Overview
• 29.2. Africa Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Advanced Recurrent Ovarian Cancer Market Competitive Landscape And Company Profiles

• 30.1. Advanced Recurrent Ovarian Cancer Market Competitive Landscape
• 30.2. Advanced Recurrent Ovarian Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Advanced Recurrent Ovarian Cancer Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Novartis International AG
• 31.4. GSK plc
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Genentech Inc.
• 31.9. Exelixis Inc.
• 31.10. Mirati Therapeutics Inc.
• 31.11. Kite Pharma Inc.
• 31.12. ImmunoGen Inc.
• 31.13. Clovis Oncology Inc.
• 31.14. Debiopharm International SA
• 31.15. Celsion Corporation

32. Global Advanced Recurrent Ovarian Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Advanced Recurrent Ovarian Cancer Market

34. Recent Developments In The Advanced Recurrent Ovarian Cancer Market

35. Advanced Recurrent Ovarian Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Advanced Recurrent Ovarian Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Advanced Recurrent Ovarian Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Advanced Recurrent Ovarian Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료